恩替卡韦联合苦参碱对慢性乙型肝炎的疗效及对炎症因子水平的影响  

Effect of entecavir combined with matrine on chronic hepatitis B and the level of inflammatory factors

作　　者：唐超 马军伟[2] 刘辉[1] 张薇[1] TANG Chao;MA Junwei;LIU Hui;ZHANG Wei(Department of Inpatient Pharmacy,Beijing Youan Hospital Affiliated to Capital Medical University,Beijing 100069,China;Department of Emergency Internal Medicine,Beijing Youan Hospital Affiliated to Capital Medical University,Beijing 100069,China)

机构地区：[1]首都医科大学附属北京佑安医院住院药房,北京100069 [2]首都医科大学附属北京佑安医院急诊内科,北京100069

出　　处：《西北药学杂志》2019年第5期673-676,共4页Northwest Pharmaceutical Journal

摘　　要：目的研究恩替卡韦联合苦参碱治疗慢性乙型肝炎的疗效及对肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)和白细胞介素-8(IL-8)水平的影响。方法随机选择在我院进行慢性乙型肝炎治疗的120例患者进行临床研究。使用随机数字表法将患者均分为对照组和观察组。对照组给予常规治疗和恩替卡韦治疗,观察组在对照组治疗的基础上采用苦参碱注射液治疗。比较2组患者治疗后的肝功能、临床疗效、炎症因子、乙肝病毒的脱氧核糖核酸(HBV-DNA)、乙型肝炎E抗原(HBeAg)转阴率及不良反应。结果观察组患者治疗总有效率为93.33%,明显高于对照组(80.00%);2组患者治疗前谷丙转氨酶(ALT)、谷草转氨酶(AST)和总胆红素(TBIL)比较,差异均无统计学意义(P>0.05),治疗后比治疗前显著降低(P<0.05),且对照组显著高于观察组,差异有统计学意义(P<0.05);2组患者治疗前TNF-α、IL-6和IL-8水平比较差异均无统计学意义,治疗后比治疗前显著降低(P<0.05),且对照组显著高于观察组;2组患者治疗后HBV-DNA转阴率及不良反应差异无统计学意义(P>0.05),观察组患者血清HBeAg转阴率为48.33%,明显高于对照组(31.67%),差异具有统计学意义(P<0.05)。结论恩替卡韦联合苦参碱能明显提高慢性乙型肝炎的临床疗效,改善患者的肝功能和TNF-α、IL-6、IL-8等炎症因子水平,且安全、可靠。Objective To study the efficacy of entecavir combined with matrine in the treatment of chronic hepatitis B and its effects on the levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and interleukin-8(IL-8).Methods 120 patients with chronic hepatitis B treated in our hospital were randomly selected for clinical study.The patients were divided into control group and observation group by random number table method.The control group was given routine treatment and entecavir treatment,while the observation group was treated with Matrine Injections on the basis of the control group.The liver function,clinical efficacy,inflammatory factors,HBV-DNA,HBeAg negative conversion rate and adverse reactions were compared between the 2 groups after treatment.Results The total effective rate of the observation group was 93.33%,which was significantly higher than that of the control group(80.00%).There was no significant difference in ALT,AST and TBIL between the 2 groups before treatment(P>0.05),but it was significantly lower after treatment than before treatment(P<0.05),and the control group was significantly higher than the observation group(P<0.05).There was no significant difference in TNF-α,IL-6 and IL-8 between the 2 groups before treatment,but after treatment,TNF-α,IL-6 and IL-8 were significantly lower than before treatment(P<0.05),and the control group was significantly higher than the observation group.There was no significant difference in HBV-DNA negative conversion rate and adverse reactions between the 2 groups after treatment(P>0.05),but the serum HBeAg translocation in the observation group was not significant.The negative rate was 48.33%,which was significantly higher than that of the control group(31.67%),and the difference was statistically significant(P<0.05).Conclusion Entecavir combined with matrine can significantly improve the clinical efficacy of chronic hepatitis B,improve the liver function and the levels of TNF-α,IL-6,IL-8 and other inflammatory factors,and is safe and reliable.

关 键 词：恩替卡韦 苦参碱 慢性乙型肝炎 炎症因子 

分 类 号：R975[医药卫生—药品]